Cytogenetic and molecular analyses of 11q23/MLL positive hematologic malignancies show that der(11) encodes the critical 5ЈMLL/3Јpartner gene transcript. The role of der(non-11) bearing the 5Јpartner/3ЈMLL fusion is less certain. The cytogenetic evidence for der(11) as the critical partner was investigated. Among 1680 cases (550 workshop and 1130 published) 31 cases displayed a three-way (29 cases) or four-way (two cases) translocation and 26 had only one of the derivatives. The critical junction created by t(11;n)(q23;n) was seen in all six cases of t(1;11)(q21;q23), in both cases of t(6;11)(q27;q23), in all six cases of t(11;19)(q23;p13), in nine of 11 cases with t(4;11)(q21;q23) and in 17 of 20 cases with t(9;11)(p21-22;q23). These findings support the evidence for der(11) encoding the critical leukemogenic fusion transcript. In contrast, additional change involving duplication of one of the derivatives resulted in duplication only of the non-critical der(non-11) as follows: +der(4)t(4;11)(q21;q23) [9/553], +der(6)t(6;11)(q27;q23) [3/61], +der(9)t(9;11)(p21-22;q23) [5/291] and +der(19)t(11;19)(q23;p13) [6/164]. A literature search of other neoplastic disorders showed that either derivative may be duplicated. Duplication of the non-critical derivative is the norm in AML patients with t(8;21)(q22;q22) or t(15;17)(q22;q12-21). We suggest that the genomic imbalance, rather than over-expression of the noncritical 5Јpartner/3ЈMLL, is likely to be the important outcome.
Introduction
Acute myeloid and lymphoblastic leukemias (AML and ALL) often display characteristic, occasionally pathognomonic, reciprocal translocations, 1,2 which -at least in principle -may result in two leukemogenic chimeric genes, located on the two derivative chromosomes generated by the rearrangement. However, the general rule seems to be that only one transcript is crucial. 3, 4 The reasons for excluding one of the fusion genes as being pathogenetically essential are manifold, such as cytogenetic investigations identifying cases with only one of the derivatives of the translocation or variant translocations revealing a conserved junction or molecular genetic studies showing consistent expression of only one of the transcripts. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Furthermore, transgenic animal experiments with various leukemia-associated gene fusions strongly indicate that just one of the two chimeric genes is sufficient to recreate a leukemic phenotype. 22, 23 Cytogenetic and molecular analyses of hematologic malignancies with translocations involving 11q23/MLL have convincingly shown that it is the der(11) that harbors the leukemogenic transcript, ie expression of the 5ЈMLL-3Јpartner chimeric protein is the important outcome. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] In view of this it might be expected that evolutionary change would involve duplication of the critical der (11) 38 similar to the frequent occurrence of duplication of der (22) siders the cytogenetic evidence which supports the molecular observations that the der(11) 38 of 11q23 translocations carries the critical fusion, gene and investigates clonal evolution involving duplication of one of the derivative chromosomes. The cases analyzed were those collected by the European 11q23 Workshop together with previously published cases with an 11q23 breakpoint. Published cases of other neoplastic cases were also reviewed to discover whether clonal evolution involves duplication of the critical or of the non-critical derivative chromosome.
Materials and methods
The basis of this study is comprised of the 550 hematologic malignancies with 11q23-rearrangements collected by the European 11q23 Workshop, the details of which are given in Secker-Walker et al. 39 The cases were cytogenetically subdivided as follows: 183 with t(4;11), 30 with t(6;11), 125 with t(9;11), 20 with t(10;11), 53 with t(11;19), 57 with del(11)(q23), and 82 with other 11q23-rearrangements. 39 For the present analysis, only translocations were investigated, ie deletions, insertions, and inversions involving 11q23 were disregarded. Malignancies with t(10;11) were also excluded because cytogenetic data on this complex abnormality cannot be properly interpreted without fluorescence in situ hybridization analyses (FISH). 40 An updated version of the Catalog of Chromosome Aberrations in Cancer 2 was used to ascertain previously published hematologic malignancies -ALL, AML, CML, myelodysplastic syndromes (MDS), and chronic myeloproliferative disorders (MPD) -with 11q23-rearrangements.
The Catalog of Chromosome Aberrations in Cancer 2 was also used to identify other neoplastic disorders, hematologic malignancies as well as solid tumors, with characteristic translocations in which gain of derivative chromosomes has been reported. A prerequisite for inclusion in the present analysis was that the gene fusion generated by the translocation should be known and that at least 10 cases should have been published.
Results
Among the 550 hematologic malignancies with 11q23-rearrangements collected by the Workshop, 24 (4.4%) displayed either only one of the derivatives of an 11q23-translocation (13 cases) or a complex translocation involving 11q23 in a three-way (10 cases) or a four-way (one case) translocation. Other examples of such abnormalities were identified in 33 (2.9%) of the 1130 previously published cases of ALL, AML, CML, MDS, and MPD with 11q23-aberrations of which 13 displayed only one of the derivatives of an 11q23 translocation and 20 had a complex translocation (Table 1) .
Among a total of 26 cases showing only one derivative chromosome, der(11) was found in all but six cases. Der (11) was seen in all six cases with t(1;11)(q21;q23), in both cases 829 Table 1 Cases displaying either only one of the derivatives of an 11q23 translocation or a variant 11q23 translocation Cytogenetic Derivative chromosome or Critical derivative subgroup variant translocation t(1;11)(q21;q23) Workshop data der(11)t(1;11)(q21;q23) der(11) der(11)t(1;11)(q21;q23) der(11) der(11)t(1;11)(q21;q23) der(11) Literature data a der(11)t(1;11)(q21;q23) der(11) der(11)t(1;11)(q21;q23) der(11) der(11)t(1;11)(q21;q23)
der (11) t(4;11)(q21;q23) Workshop data t(1;4;11)(p36;q21;q23) der(11) t(1;4;11;12)(q21;q21;q23;q13) der(11) der(11)t(4;11)(q21;q23) der(11) t(11;4;13)(q23;q21;q34) b der(4) Literature data a t(4;6;11)(q21;p21;q23) der(4) t(4;11;12)(q21;q23;p13) der(11) t(4;11;13)(q21;q23;q14) der(11) t(4;11;15)(q21;q23;q21) der(11) t(4;11;17)(q21;q23;q11) der(11) t(4;11;19)(q21;q23;q13) der(11) der(11)t(4;11)(q21;q23)
der (11) t(6;11)(q27;q23) Literature data a t(5;6;11)(q12;q27;q23) der(11) der(11)t(6;11)(q27;q23)
der (11) t(9;11)(p21-22;q23) Workshop data t(X;9;11)(p21.1;p22;q23) der(11) t(1;9;11)(q25;p21;q23) der(11) t(1;9;11)(q31;p21;q23) der(11) t(3;9;11)(p12;p21;q23) der(11) t(5;9;11)(p13;p22;q23) der(11) der(9)t(9;11)(p22;q23)
der (9) c der(9)t(9;11)(p22;q23) der(9) c t(9;9;11)(p13;p22;q23) der(11) t(9;11;15)(p22;q23;q24) der(11) der(11)t(9;11)(p21;q23) der(11) Literature data a t(1;9;11)(q23;p21;q23) der(11) t(1;9;11;21)(p34;p22;q23;q22) der(11) t(9;9;11)(p24;p21;q23) der(11) der(9)t(9;11)(p21;q23) der(9) t(9;11;11)(p21;q23;p13) der(11) t(9;11;13)(p22;q23;q34) der(11) t(9;11;14)(p22;q23;q24) der(11) t(9;11;16)(p22;q23;p13) der(11) t(9;11;18)(p22;q23;q12) der(11) t(9;11;22)(p22;q23;q11)
der (11) t(11;19)(q23;p13) Workshop data der (11) der (11) Other Workshop data der(11)t(1;11)(q31;q23) der(11) der(11)t(1;11)(q31;q23) der(11) der(11)t(3;11)(p13;q23) der(11) der(11)t(10;11)(q22;q23) der(11) der(11)t(11;12)(q23;q13) der(11) Literature data a der(1)t(1;11)(q32;q23) der(1) der(5)t(5;11)(q13;q23) der(5) der(11)t(1;11)(q12;q23) der(11) der(11)t(3;11)(p11;q23) der(11) der(11)t(3;11)(p21;q23) der(11) der(11)t(11;12)(q23;q13) der(11) der (12) with t(4;11)(q21;q23), in the one case with t(6;11)(q27;q23) and in the one case with t(11;19)(q23;p13.3). However, der(11) was found in only nine of 12 cases with an 'other' translocation and in only one of the four cases with t(9;11)(p21-22;q23). In 29 of the 31 cases with a complex translocation the 11q23 breakpoint was juxtaposed to the well recognised chromosomal locations known to result in one of the critical 5ЈMLL-3Јother gene fusions namely 4q21 (seven cases), 6q27 (one case), 9p21-22 (16 cases), and 19p13 (five cases). The two exceptional cases had breakpoints at both 4q21 and 11q23 but 11q23 was juxtaposed to 13q34 and to 6p21 respectively (Table 1) . Only duplication of der(4), der(6), der(9), and der(19) -never the der(11) -was found as a secondary change to t(4;11), t(6;11), t(9;11), and t(11;19), respectively ( Table 2) . Gain of a derivative has so far not been reported in malignancies with t(X;11)(q13;q23), t(1;11)(p32;q23), t(1;11)(q21;q23), t(11;16)(q23;p13), or t(11;17)(q23;q21).
The literature search revealed that either the non-critical or the critical derivative may be duplicated as a secondary aberration in malignancies with t(X;18), t(1;19), t(2;5), t(2;13), t(3;21), t(8;21), t(9;22), t(12;21), and t(15;17) ( Table 3) . Gain of a derivative has so far not been reported in the following neoplastic disorders: AML with t(3;5)(q25;q34), lipoma with t(3;12)(q27-28;q15), AML/MDS with t(6;9)(p23;q34), AML with t(7;11)(p15;p15), AML with t(8;16)(p11;p13), peripheral primitive neuroectodermal tumors with t(11;22) (q24;q12), myxoid liposarcomas with t(12;16)(q13;p11), AML with t(16;16)(p13;q22), or AML with t(16;21)(p11;q22).
Discussion
The present compilation of derivative and complex translocations involving 11q23 in hematologic malignancies strongly supports previous conclusions based on similar cytogenetic investigations, namely that when only one of the derivatives is present it is almost always the der (11) and that most complex 11q23 translocations result in the juxtaposition of 11q23, apparently in the correct orientation, with a chromosomal region known to contain a fusion partner gene to MLL (Table  1) . [24] [25] [26] 31, 35 These data thus agree well with expression studies showing that the consistent chimeric product is the 5Ј portion Table 2 Gain of derivative chromosomes as secondary changes in hematologic malignancies with 11q23-translocations of MLL fused to various partner genes and that this chimeric gene is located on the derivative chromosome 11. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] We did, however, identify five cases with non-reciprocal t(4;11)/t(9;11) that lacked the der(11), ie two variant 4;11 translocations with only the der(4) and three with only the der(9) of the 9;11 translocation (Table 1) . Furthermore, the only derivatives of the 11q23-translocations in the subgroup 'other' were non-der(11) in three of the cases (Table 1 ). The latter aberrations may, however, not result in rearrangements of the MLL gene and would hence be uninformative in this regard. The MLL gene was rearranged in two cases with der(9) only but it is of course possible that the MLL gene was not rearranged in all malignancies harboring only der(4)t(4;11) and der(9)t(9;11). Another possibility would be that the cytogenetic origin of these changes was more complex than is usually seen in translocations between 11q23 and 4q21/9p21-22, but that the molecular consequences were the same as for standard t(4;11) and t(9;11). That this may be the case has previously been shown in other malignancies using FISH, revealing for example 'aberrant' locations of fusion genes, such as BCR-ABL fusion on the der(9) instead of on the der (22) in CML with standard t(9;22), and the presence of critical derivative chromosomes that were not identified by conventional cytogenetics. 41, 42 In this study we identified two examples of three-way translocations of 11q23 and 4q21. We have to consider the possibility that the critical junction in these cases may be between 5Ј MLL and a gene on the third chromosome involved in the translocation. Hence, the few exceptions identified in the present study cannot refute the hypothesis that der(11) usually harbors the critical, leukemogenic fusion transcript in hematologic malignancies with 11q23/MLL-rearrangements.
Whereas the der(11) as a rule seems to be of utmost importance for the initiation of the leukemogenic process, duplication of this derivative chromosome is apparently not essential for the progression, or at least the cytogenetic evolution, of 11q23-positive leukemias. The present study, somewhat unexpectedly, revealed that only +non-der(11) was found as a secondary change, ie +der(4), +der(6), +der (9) , and +der (19) in hematologic malignancies with t(4;11), t(6;11), t(9;11), and t(11;19), respectively ( Table 2 ). This might suggest that duplication of the non-der(11) confers a selective advantage to the leukemic cells by increasing the amount of the recipro- cal fusion transcripts AF4-MLL, AF6-MLL, AF9-MLL, ENL-MLL and ELL-MLL even though these chimeric transcripts are not detectable in all cases. [27] [28] [29] [30] A possible biological importance for the fusion genes which are not consistently expressed has been suggested for RARA-PML in t(15;17)-positive acute pro myelocytic leukemia (APL) and ABL-BCR in t(9;22)-positive CML. 13, 43 A more likely explanation might be that the gain of one or several other genes located on these derivatives has a role in clonal evolution. Such a genomic imbalance occurring during cytogenetic evolution fits well with what is usually seen in hematologic and solid malignancies, ie secondary changes are, for reasons at present unknown, almost always cytogenetically unbalanced. [44] [45] [46] Since the present data revealed that it was the 'non-critical' derivative that was duplicated as a secondary change in 11q23-positive hematologic malignancies we extended the analysis to include gains of derivative chromosomes of characteristic translocations in other neoplastic disorders. As seen in Table 3 , both gain of the non-critical and the critical derivatives has been found as secondary aberrations, although it was the derivative harboring the, supposedly, pathogenetically important gene fusion that was duplicated during clonal evolution in most instances, ie +der(13)t(2;13) in rhabdomyosarcomas, +der(19)t(1;19) in ALL, +der(21)t(12;21) in ALL, and +der(22)t(9;22) in ALL, AML and CML. However, common exceptions were noted. APL with the PML-RARA fusion, which is located on the der(15), relatively frequently showed duplication of the derivative chromosome 17, in the form of an ider(17)(q10)t (15;17) , containing the reciprocal RARA-PML. Furthermore, +der(21)t(3;21) in CBFA2-EAP,EVI1,MDS1-positive hematologic malignancies and +der(21)t(8;21) in CBFA2/ETO-positive AML were the only additional derivatives seen in these disorders, although the leukemogenic transcripts are encoded by the der(3) and der(8), respectively (Table 3) . Taking all these data together, we suggest that it is the genomic imbalances incurred by additional derivative chromosomes that are important, not the duplication and possible overexpression of the chimeric genes, be they critical or non-critical. Furthermore, the present findings unequivocally show that the location of a consistently expressed fusion gene cannot be deduced from the duplication of a particular derivative chromosome during cytogenetic evolution.
